San Carlos, United States
ELEGEN, founded in 2017 and based in the United States, is at the forefront of the synthetic biology revolution. Their mission is encapsulated by their slogan: "Unlock the promise of synthetic biology by accelerating the Design-Build-Test-Learn cycle."
The company is pioneering technologies to achieve rapid, cost-effective, and high-quality DNA writing, positioning themselves as catalysts for new applications and markets. ELEGEN aims to harness the ability to reprogram biology to address critical global challenges, aligning with the growing demands in Biotechnology, Health Care, and Life Sciences.
With leadership from Dr. Matthew Hill, a Stanford PhD, and a strong advisory board, including Dr. Marc Unger, ELEGEN maintains a robust scientific and entrepreneurial foundation. Recently securing a $35.00M Series B investment from reputable firms such as Andreessen Horowitz, 8VC, and KdT Ventures, the firm is well-positioned for growth and innovation.
BioVentures Institute